Japan's YTD OP Growth Now at 2% with Net Income Flat YoY
With 365 names already reporting 3Q numbers the picture is starting to shape up. Looking at the overall market, YTD OP is up 2.3% and Net Income is...
323 Views
Takeda Pharmaceuticals - Initiating Coverage - In Pursuit of Growth Drivers
We initiate coverage on Takeda Pharmaceutical with a neutral rating and a DCF based target price of ¥ 5,200. We expect the Entyvio, Ninlaro and...
165 Views
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
AML represents one of the largest hematologic cancer populations with one of the worst survival rates. Global prevalence is expected to increase at...
522 Views
Trintellix (Vortioxetine) – Selective Serotonin Reuptake Inhibitor (SSRI) And Partial Agonist
While sales of Takeda's long listed products (~ 20% of sales in FY15) continue to decline, expectations remain bleak for its late stage pipeline.We...
190 Views
Ninlaro (Ixazomib) - Oral Proteasome Inhibitor
Ninlaro (ixazomib, formerly MLN9708, Takeda) is the first and the only oral proteasome inhibitor, approved by USFDA (Nov’15) (three months ahead...
210 Views